Pharmacopeia Will Acquire MSI, Expand Drug Discovery Efforts | GenomeWeb

PRINCETON, NJ--Earlier this month Pharmacopeia here announced an agreement under which it will acquire San Diego-based Molecular Simulations in a stock swap deal. The boards of both companies have approved the transaction, which is valued at approximately $140 million. The acquisition, which will result in a merger of complementary drug-discovery technologies, should close during the second quarter of this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.